lamivudine [Ligand Id: 12673] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL141 (BCH 189, (-)-, Epivir, Epivir-hbv, GR 109714X, GR-109714X, Lamivudina, Lamivudine, Lamivudine teva, Lamivudinum, NSC-760061, Virolam, Zeffix) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| Core antigen in Hepatitis B virus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075091] [UniProtKB: Q03732] | ||||||||
| ChEMBL | Inhibition of capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level measured after 72 hrs by PCR analysis | B | 4 | pIC50 | >100000 | nM | IC50 | Eur J Med Chem (2019) 176: 41-49 [PMID:31091479] |
| ChEMBL | Inhibition of capsid protein in Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 4 uM supplemented with fresh medium containing compound every 2 days and measured after 6 days by RT-PCR analysis | B | 7 | pIC50 | <100 | nM | IC50 | Eur J Med Chem (2019) 176: 41-49 [PMID:31091479] |
| ChEMBL | Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in tetracycline-induced cccDNA formation by measuring reduction in HBe antigen secretion after 14 days by ELISA | B | 5 | pEC50 | >10000 | nM | EC50 | Eur J Med Chem (2017) 138: 407-421 [PMID:28688280] |
| ChEMBL | Inhibition of capsid protein in HBV infected in human HepDES19 cells assessed as inhibition of viral replication incubated for 3 days by strand preferential qPCR analysis | B | 6.43 | pEC50 | 370 | nM | EC50 | Eur J Med Chem (2021) 225: 113780-113780 [PMID:34438123] |
| Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL247] [UniProtKB: Q72547] | ||||||||
| ChEMBL | In vitro antiviral activity against HIV-1 Reverse transcriptase M184V mutant | B | 4.3 | pEC50 | >50000 | nM | EC50 | Bioorg Med Chem Lett (2003) 13: 1993-1996 [PMID:12781181] |
| ChEMBL | In vitro antiviral activity against HIV-1 Reverse transcriptase wild type | B | 7.38 | pEC50 | 42 | nM | EC50 | Bioorg Med Chem Lett (2003) 13: 1993-1996 [PMID:12781181] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
